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Abstract
Purpose—To compare clinical, immunohistochemical and gene expression models of prognosis
applicable to formalin-fixed, paraffin-embedded blocks in a large series of estrogen receptor positive
breast cancers, from patients uniformly treated with adjuvant tamoxifen.
Methods—qRT-PCR assays for 50 genes identifying intrinsic breast cancer subtypes were
completed on 786 specimens linked to clinical (median followup 11.7 years) and
immunohistochemical (ER, PR, HER2, Ki67) data. Performance of predefined intrinsic subtype and
Risk-Of-Relapse scores was assessed using multivariable Cox models and Kaplan-Meier analysis.
Harrell’s C index was used to compare fixed models trained in independent data sets, including
proliferation signatures.
Results—Despite clinical ER positivity, 10% of cases were assigned to non-Luminal subtypes.
qRT-PCR signatures for proliferation genes gave more prognostic information than clinical assays
for hormone receptors or Ki67. In Cox models incorporating standard prognostic variables, hazard
ratios for breast cancer disease specific survival over the first 5 years of followup, relative to the
most common Luminal A subtype, are 1.99 (95% CI: 1.09–3.64) for Luminal B, 3.65 (1.64–8.16)
for HER2-enriched and 17.71 (1.71–183.33) for the basal like subtype. For node-negative disease,
PAM50 qRT-PCR based risk assignment weighted for tumor size and proliferation identifies a group
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with >95% 10 yr survival without chemotherapy. In node positive disease, PAM50-based prognostic
models were also superior.
Conclusion—The PAM50 gene expression test for intrinsic biological subtype can be applied to
large series of formalin-fixed paraffin-embedded breast cancers, and gives more prognostic
information than clinical factors and immunohistochemistry using standard cutpoints.
Introduction
A number of gene expression technologies and statistical models have reported methodologies
to identify breast cancer patients with estrogen receptor positive, node negative (N0) disease
that may be adequately managed with five years of tamoxifen monotherapy (1–5). However,
these studies often included patients with tumors already associated with established low risk
biomarkers, for example low grade histology, low Ki67 based proliferation index and favorable
surgical stage. It therefore remains controversial whether genomic assays should be applied
routinely, or whether surgical stage and a limited number of immunohistochemical markers
will, in most cases, be adequate and less costly (6).
The clinical significance of continued efforts in this area is relevant for decisions regarding
both chemotherapy and endocrine agents, as patients at low risk after five years of tamoxifen
monotherapy could be spared the morbidity associated with extended aromatase inhibitor
therapy (7). Studies that address this issue are few, because extremely long follow up and
information on breast cancer specific mortality are required. Furthermore, since frozen tumor
archives are unavailable from suitably large patient populations, gene expression technologies
must be applicable to degraded RNA extracted from formalin fixed paraffin embedded tissues
that are necessarily more than a decade old.
Our group has assembled and published several technological and statistical approaches to
address prognosis in ER+ breast cancer. We therefore sought to compare clinicopathological,
immunohistochemical and molecular methodologies in a single independent test set in order
to identify the best approach. Importantly, we focused on fixed statistical models that were
previously trained on independent data sets to avoid overoptimistic results. The models we
report in this paper include the use of standard pathological factors, such as centrally-reviewed
histological grade, as incorporated into Adjuvant! Online (8), models based on
immunohistochemistry (IHC) for biomarkers of intrinsic subtypes (6), and a gene expression
assay using fifty genes (PAM50). The latter represents a reduced gene set, amenable to assay
by techniques such as quantitative real time reverse transcriptase PCR (qRT-PCR), that
accurately identifies the major intrinsic biological subtypes of breast cancer and generates risk
of relapse scores (9). The investigation utilized a large independent cohort of formalin-fixed,
paraffin-embedded pathology specimens from patients with ER+ breast cancer, all M0 but
otherwise representing a spectrum of T and N stages including a large fraction of node positive
patients. All patients received adequate local treatment, five years of tamoxifen therapy but no
adjuvant chemotherapy, and were followed for relapse free (RFS) and disease specific survival
(DSS) for over a decade.
Methods
Patient and sample characteristics
The study cohort was accrued from female patients with invasive breast cancer, diagnosed in
British Columbia between 1986 and 1992. Cancer tissue from these patients had been frozen
and shipped to Vancouver Hospital for central ER and progesterone receptor (PR) testing by
dextran-coated charcoal ligand binding assay. The PAM50 assay was conducted on the portion
of this tissue that was formalin-fixed and paraffin-embedded for histologic correlation.
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Characteristics of this cohort have been previously described (6), and the same source blocks
were used to assemble tissue microarrays for previously published studies on ER (10), HER2
(11), PR (12), Ki67, cytokeratin 5/6 and epidermal growth factor receptor (6,13). Quantitative
ER was determined using the Ariol automated digital imaging system (14), and the same
method was applied for PR. For this study, we selected samples from patients with ER+ tumors
by immunohistochemistry (IHC) who had received tamoxifen as their only adjuvant systemic
therapy. Provincial guidelines from that time period recommended tamoxifen for women >50
years of age, whose ER status was positive or unknown, and who were either node positive or
had lymphovascular invasion. Cohort identification and sample selection for this study are
summarized as per REMARK criteria (15) in Supplementary Table 1.
RNA preparation, qRT-PCR, and assignment of biological subtype and Risk-of-elapse (ROR)
score
H&E sections from each block were reviewed by a pathologist (TON). Areas containing
representative invasive breast carcinoma were selected and circled on the source block. Using
a 1.0 mm punch needle, at least two tumor cores were extracted from the circled area. Details
of RNA preparation from paraffin cores, the qRT-PCR assay for the PAM50 panel and
reference genes, and how these results allow assignment into Luminal A, Luminal B, HER2-
enriched and Basal-like subtypes, and the independently-trained ROR-S (Risk Of Relapse
based on Subtype), ROR-T (-Tumor size weighted model), ROR-P (-Proliferation weighted
model) and ROR-PT (Proliferation and Tumor size weighted) risk score assignments are
presented in Supplementary Methods. For clarity, the term ROR-T is now used for the same
model described in our earlier publication as ROR-C (“clinical”) (9).
Relation of clinicopathological factors, intrinsic subtypes and risk of relapse (ROR) scores
to clinical outcome
Statistical analyses were conducted using SPSS v16.0 and R v2.8.0. Univariable analyses of
tumor subtype against breast cancer relapse-free survival (RFS) and disease-specific survival
(DSS) were performed by Kaplan-Meier analysis with log rank test. Multivariable analyses
were performed against the standard clinical parameters of tumor size, nodal status, histological
grade, patient age and HER2 status. HER2 scores were centrally-determined based on assay
of adjacent cores from the same source blocks, assembled into tissue microarrays and subjected
to IHC and fluorescent in situ hybridization (FISH) analysis using clinical-equivalent protocols
(11). Cox regression models (16) were built to estimate the adjusted hazard ratios of the qRT-
PCR-assigned breast cancer subtypes, as well as ROR scores categorized by published cut-
points and as a continuous variable. IHC-based subtypes were assigned as previously defined
(6). The online decision making tool Adjuvant! Online (www.adjuvantonline.com), previously
validated on the British Columbia population cohort (8), was used to generate breast cancer
relapse-free and disease-specific survival estimates for each patient in this cohort. Only cases
with information for all the covariates were included in the analyses. Smoothed plots of
weighted Schoenfeld residuals were used to assess proportional hazard assumptions (17) and
time stratifications were employed where hazards were not proportional over the entire follow
up period.
The C-index (18) is defined as the probability that risk assignments to members of a random
pair are accurately ranked according to their prognosis. The number of concordant pairs (order
of failure and risk assignment agree), discordant pairs (order of failure and risk assignment
disagree), and uninformative pairs are tabulated to calculate the measure. C-index values of
0.5 indicate random prediction and higher values indicate increasing prediction accuracy.
Variability in the C-index for each predictor and p-values from comparisons were estimated
from 1000 bootstrap samples of the risk assignments. Calculation was performed using the
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rcorr.cens function implemented in the Hmisc (19) library for R statistical software version
2.8.1 (http://www.R-project.org)
Results
Intrinsic subtyping of ER positive, tamoxifen-treated breast cancer using the PAM50 assay
RNA was extracted from pathologist-guided tissue cores from 991 formalin-fixed, paraffin-
embedded breast cancer specimens. 811 samples yielded sufficient RNA for analysis (at least
1.2 ug total RNA at a concentration ≥ 25 ng/uL). Template was technically sufficient in 786
cases, based on all internal housekeeper gene controls being expressed in the sample above
background. Clinical characteristics for the patients included in the PAM50 analysis are
presented in Table 1 (Supplementary Tables S2 and S3 provide details stratified by node status).
Based on the nearest PAM50 centroid algorithm, intrinsic breast cancer subtypes were assigned
using gene expression as follows: 372 samples (47.3%) were Luminal A, 329 (41.9%) Luminal
B, 64 (8.1%) HER2-enriched, 5 (0.6%) Basal-like, and 16 (2.0%) Normal-like. Thus, while all
cases in this study were positive for ER by centrally-assessed IHC analysis on a tissue
microarray (10), and 98.8% were also positive by dextran-charcoal coated biochemical assay
(Table 1), the gene expression panel nevertheless assigned 9% of cases into non-luminal
subtypes, mostly HER2-enriched. This phenomenon has been previously observed when
interrogating published datasets for expression of the PAM50 genes (9). For the sixteen cases
assigned as Normal-like, histology was reviewed from adjacent tissue cores, and in 14 of 16
cases invasive cancer cells were absent or rare. Normal-like cases were therefore excluded
from outcome analyses, as a breast cancer subtype could not be confidently assigned due to
insufficient tumor content.
The intrinsic biological subtypes were strongly prognostic by Kaplan-Meier analysis (Figures
1A and 1B). In the British Columbia population at the time these samples were originally
acquired, many patients with a clinically low-risk profile received no adjuvant systemic therapy
(8). In contrast, those receiving adjuvant tamoxifen (the subjects of this study) had tumors that
were mostly node positive, high grade and/or exhibited lymphovascular invasion, and therefore
constitute a higher risk group with overall 10 year RFS of 62% and DSS of 72%. Those assigned
by the PAM50 assay to Luminal A status had a significantly better outcome (10 year relapse
free survival 74%, disease-specific survival = 83%) than Luminal B, HER2-enriched or basal
like tumors (Figure 1A for RFS and Figure 1B for DSS). The ROR risk-of-relapse algorithms
(9) were originally trained on microarray data from node negative patients who received no
adjuvant systemic therapy, and have not previously been applied to a population
homogeneously-treated with adjuvant tamoxifen, nor to a series containing large numbers of
node positive cases, nor to the endpoint of disease specific survival. In this data set ROR-S (a
model based solely on gene expression) nevertheless showed performance consistent with our
previous report (Figures 1C and 1D). Multivariable Cox models were constructed to test the
independent value of PAM50 subtyping against standard clinical and pathological factors
including age, histological grade, lymphovascular invasion, HER2 expression, nodal status,
and tumor size. To meet proportional hazard assumptions, multivariable models were assessed
with the time axis split at 5 years (20), as HER2-enriched and basal-like tumors (Figure 1A
and 1B) and ROR-S high category tumors (Figure 1C and 1D) had a much higher event rate
in the first five years than subsequently. The intrinsic biological subtype and ROR-S remained
significant in the multivariable models for DSS (Table 2) and RFS (Supplementary Table S4),
particularly in the first five years, as did pathological staging variables (tumor size and node
status). However histological grade, lymphovascular invasion and clinical HER2 status,
significant in univariable analysis in this cohort, no longer contributed significant independent
prognostic information when the multivariable analysis included the PAM50 assignments.
Nielsen et al. Page 4













Comparisons between gene expression and clinical assays for hormone receptors and
proliferation
In a case that is ER positive by immunohistochemistry, additional information about hormone
receptor expression can be obtained in several ways, including dextran-coated charcoal ligand
binding assay, quantitative immunohistochemistry for ER, or equivalent measures of
progesterone receptor (PR). Most published assays for breast cancer prognosis in ER+ disease
include tumor growth rate as one of the parameters in the statistical model, and this dataset
was previously assessed in detail for immunohistochemical Ki67 index (6). The PAM50 qRT-
PCR data allows detailed quantitative assessment of the functionality of the estrogen response
pathway (8 gene luminal signature) as well as a proliferation signature based on the mean
expression of eleven genes linked to cell cycle progression (trained on published data, as per
Supplementary Methods). The availability of all these measurements (10) provides an
opportunity to determine which approach most accurately captures the prognostic effect of
estrogen pathway biomarkers and tumor growth rate in a direct comparison (Figure 2). Given
a randomly selected pair of subjects, the concordance index (C-index) is the probability that
the patient assigned the more extreme risk score actually has a worse prognosis. A value of 0.5
indicates discrimination that is no better than chance prediction, and a value of 1 indicates
perfect discrimination of samples. Using the C-index to compare prognostic capacity in this
uniformly tamoxifen-treated cohort, the combination of luminal genes measured by the PAM50
yields more prognostic information than other methods of hormone receptor analysis, but the
differences are not significant. Although Ki67 index by immunohistochemistry appears to
outperform quantitative ER, the proliferation signature provides the most robust approach for
the prediction of both RFS and DSS (Figure 2, Supplementary Table S5). Multivariable
analysis indicated that the Ki67 immunohistochemical assay did not contribute significant
independent information to prognostic models for either node negative or node positive breast
cancer patients, when information on the proliferation signature is included (Supplementary
Table S6).
Comparison of fixed models of prognosis in node negative breast cancer
For formal model comparisons, data was generated on four fixed approaches, without any
element of training within the test set: a) clinical model based on Adjuvant! Online, b) IHC-
based (incorporating data on Ki67 and HER2), c) the ROR-S approach based on PAM50 gene
expression alone, and d) the proliferation signature alone and as incorporated into the ROR-P
risk model using a beta coefficient weighting for proliferation (described in Supplementary
Methods). Adjuvant! Online incorporates full tumor size staging information; to account for
the influence of tumor size the biomarker models were also weighted by a beta coefficient (T)
that incorporated the prognostic information associated with T1 status versus higher T stage
(the level of detail available in the independent training sets). This approach created IHC-T,
ROR-T and ROR-PT models. In addition, the strong independent influence of N stage was
accounted for by conducting the analysis separately in the N0 and N+ populations. C-index
assessments showed superiority of the biomarker models over the purely clinical Adjuvant!
Online model in the node negative population, with the ROR-PT approach providing the most
prognostic information (Figure 3A). In multivariable analysis, the addition of ROR-P to a
model of ROR-S results in a significant increase in explained prognostic variation (RFS
p=0.0032; DFS p=0.0015); ROR-PT is also significant after conditioning on ROR-S (RFS p=
0.0023; DFS p=0.0015) but not ROR-P (RFS p=0.12; DFS p=0.13). A continuous score based
on the ROR-PT was generated to translate the data into an individual RFS and DSS risk
assessment tool (Figure 3B). Kaplan Meier analysis illustrates the ability of the ROR-PT model
to identify patients who have an extremely high chance (>95%) of remaining disease free
(Figure 3C) and alive beyond 10 years (Figure 3D). In contrast, our previously published IHC
model (6), could not identify a group with sufficiently favorable outcomes that five years of
tamoxifen might be considered adequate treatment (i.e. <90% 10 yr RFS; Figures 3E and 3F).
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Comparison of fixed models of prognosis in node positive breast cancer
For node positive disease, C index analysis (Figure 4A) supports the conclusion that the ROR-
T score produces the best prognostic model; in contrast to N0 disease, the proliferation
signature added relatively little information and proliferation weighting (ROR-PT) did not
yield a superior model. Adjuvant Online! performed almost as well, but had the advantage of
incorporating the actual number of involved lymph nodes. This information was not available
in the independent training sets used to build the ROR models, and so could not be used in the
current analysis (which can however serve to train future models incorporating number of
involved lymph nodes). The continuous score model for node positive disease (Figure 4B)
produces a very broad range of prognosis, similar to N0 disease, although few patients have a
prognosis in the range where tamoxifen monotherapy for five years would be considered
sufficient treatment. While there were large and highly significant differences in survival in
ROR-defined risk groups, Kaplan Meier analysis (Figures 4C–4D) illustrates that even patients
in the lowest risk ROR group are still subject to relapses and late deaths from breast cancer,
particularly after the fifth year of follow up. The immunohistochemistry-based risk model
incorporating Ki67 and HER2 also produces a statistically significant prognostic impact for
RFS (Figure 4E) and DSS (Figure 4F), although these differences are narrower than those
achieved by the gene expression-based model.
DISCUSSION
Previous studies have established that intrinsic biological signatures are present and have
prognostic significance in breast cancer cohorts from multiple different institutions, profiled
with several gene expression microarray platforms (21–24). In order to identify these subtypes
on standard formalin-fixed, paraffin-embedded pathology specimens, we developed a qRT-
PCR test based on a panel of 50 genes (9). The analysis reported here applied this test to a
series of paraffin blocks with > 15 years detailed followup.
Whereas previously assessed cohorts consisted mainly of low risk women receiving no
adjuvant systemic therapy, or were heterogeneously-treated, the cases in the current study are
all women with estrogen receptor positive breast cancer who received endocrine therapy as
their sole adjuvant treatment, a group of particular clinical importance and contemporary
relevance. In this analysis we sought to compare different technologies for predicting long term
outcomes for such patients. In this study cohort, patients were diagnosed with node positive
or higher risk N0 disease. Only 8% of the N0 population had grade 1 disease and 55% exhibited
lymphovascular invasion (Table S2). Under the current standard of care in most countries the
majority of these patients would now be treated with adjuvant chemotherapy (25) and extended
endocrine therapy. Using a series of fixed models trained in independent data sets, we compared
a standard approach using clinico-pathological information (Adjuvant! Online), to our
published Luminal B discriminator based on Ki67 and HER2 immunohistochemistry
additionally weighted for T stage (IHC-T), and to PAM50 gene expression based ROR models
weighted for T stage (ROR-T and ROR-PT). In node-negative patients, the ROR-PT approach
was the most accurate and was able to identify patients in whom 5 years of tamoxifen may be
adequate treatment based on the very low late relapse rate in the 5 to 10 year window (Figure
3C). In node positive disease, the PAM50 approach represents an advance in prognostication,
but late relapses and deaths were seen even in the lowest risk group identified using the best
ROR model. Unlike in N0 disease, proliferation signature weighting did not improve the C
index in node positive disease.
On this cohort, detailed centrally-determined immunohistochemical analyses have previously
been performed and published (6,10–13,26). C-index, Kaplan-Meier and Cox model analyses
show that immunohistochemical approaches do work and provide significant prognostic
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information. However, the PAM50-based models are superior in terms of adding significant
additional information and in their capacity to identify a particularly low-risk group of women.
We view these PAM50 models, derived from archival formalin fixed RNA, as a potential
replacement for grade, hormone receptor, Ki67 and HER2 based prognostic models, but not
as a replacement for pathological stage (as tumor size and nodal status remain independent
predictors in multivariable models that include PAM50 based prognostic information). One
weakness of our approach is that our current accounting for pathological stage is over-
simplified due to the limited stage distributions and clinical information in our training sets.
We analyzed the data as either node negative or node positive, and accounted for T stage by
categorizing the samples as either T1 or greater. A future aim is to integrate the PAM50 data
into the Adjuvant! Online approach (27) to more completely account for the prognostic
influence of pathological stage. To achieve this we would need to construct a training set that
adequately includes all the 5 categories of T size and four categories of N stage used in
Adjuvant! Online, in order to gauge the prognostic weight of these pathological stage categories
in the setting of PAM50 information. Additionally, incorporation of all immunohistochemical
data as continuous variables in a combined model may improve its prognostic value. The
current series contains sufficiently detailed clinical and immunohistochemical information to
contribute to such detailed comparisons, as a training set requiring further validation.
An additional caveat to our study is that the population was strongly biased towards higher
risk breast cancers and so likely underestimates of the number of patients in the broader, node
negative population for whom adjuvant tamoxifen would represent adequate treatment. The
current generation of adjuvant aromatase inhibitor trials would be an appropriate setting to
address the value of our approach further. We accept the possibility that a better model using
Ki67 at a different cut point could be developed. However since we were focused on comparing
fixed models, we used our published approach. Further work on the Ki67 model and cut point
optimization will require independent data sets.
In comparison with other signatures such as the recurrence score and genomic grade index
(1,28,29), the PAM50 has the potential advantage of discriminating high risk patients into
Luminal B, HER2-Enriched and Basal-like subtypes, who are likely to respond differently to
the main systemic therapy options (endocrine, anti-HER2, and anthracycline vs. non-
anthracycline vs. taxane chemotherapy regimens). The assay requires neither frozen tissue
(30) nor manual microdissection of cut sections(1), and can be readily applied to standard
paraffin blocks including archival tissues from clinical trials. Currently available assays such
as Mammaprint (31) and OncotypeDX (32) were optimized to recognize particularly low risk
patients from among a node negative early stage population who did not receive chemotherapy.
Because intrinsic subtyping is designed to identify discriminative biological features of breast
cancer, rather than being derived around clinical outcome in a specific population, this
approach is particularly likely to extrapolate well onto other patient cohorts (33). The current
study demonstrates the ability of PAM50 to recognize a very low risk prognostic group among
women receiving tamoxifen and no chemotherapy, similar to the Oncotype Dx assay(34,35).
A direct comparison of different expression profile approaches may become possible in the
future through a reanalysis of cohorts with the PAM50 that have already been analyzed by
OncotypeDX, since both assays can be applied to the same source material.
Our inability to identify a group of patients with node positive disease in whom five years of
tamoxifen is adequate is reminiscent of the recent findings from the Southwest Oncology
Group, who also found that a molecular signature for good outcome in N0 disease failed in
node positive disease in this regard (35). It would be relevant to study a series of patients treated
with extended adjuvant aromatase inhibitor therapy, who will have even lower residual risk,
as some of the patients in the low risk N+ group may simply require longer treatment with
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modern endocrine therapy rather than chemotherapy. The development of new approaches for
defining prognosis in N+ disease is also warranted. We have already established the
preoperative endocrine prognostic index (PEPI), which demonstrated that the “on endocrine
treatment” Ki67 value is more effective than baseline Ki67 for the identification of patients
with clinical stage 2 and 3 disease who have excellent long term outcomes after neoadjuvant
endocrine therapy (36). A comparison between Ki67 and the PAM50 based proliferation
signature in the neoadjuvant endocrine therapy setting is therefore one logical next step. The
applicability of this test to formalin-fixed paraffin-embedded tissues will make possible its use
on large clinical trial archives that address this issue (37). The results of our study highlight
the feasibility of measuring multi-gene expression panels on such series as a means for
demonstrating clinical utility, using a method readily applicable to prospective clinical samples
that provides more prognostic information than clinical or standard immunohistochemical
approaches.
Description of how this work might be applied to future practice of cancer
medicine
Molecular intrinsic subtyping reveals the major biological categories of breast cancer.
Herein we demonstrate adaptation of a 50 gene intrinsic subtyping signature for testing
standard paraffin blocks. Using a large, homogeneously treated cohort of breast cancer
patients, we directly compare gene expression results to high quality clinical and central
immunohistochemical data. We show the PAM50 approach to be superior as a prognostic
test, specifically able to identify an ultra-low risk group who may not need chemotherapy.
Based on these results, intrinsic subtyping tests are now being applied to randomized clinical
trials series in Canada and the USA to assess predictive capacity (already underway for
response to endocrine therapy, anthracyclines and taxanes, with further studies under
consideration). Should such studies prove a predictive value for intrinsic subtyping, this
test could be clinically implemented in a similar form, as it has been designed for application
on standard laboratory specimens.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Kaplan-Meier survival analysis of intrinsic subtype (panels A and B) and Risk of Relapse score
(ROR-S, panels C and D), as determined by PAM50 gene expression measurement by qRT-
PCR performed on paraffin blocks from women with invasive breast carcinoma, treated with
adjuvant tamoxifen. The number of events and total number of patients in each group is shown
beside each curve’s description. RFS = relapse-free survival (panels A and C). DSS = breast
cancer disease-specific survival (panels B and D; excludes two cases with unknown cause of
death).
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C-index estimates of relapse free (RFS) and disease-specific (DSS) survival for different
measures of hormone receptors and proliferation. DCC = dextran-coated ligand binding assay.
IHC = % positive nuclei by immunohistochemistry. The Luminal and Proliferation measures
are the means of normalized qRT-PCR values across 8 and 11 signature genes respectively, as
described in Supplementary Methods. P-values were estimated from 1000 bootstrap samples.
Single asterisk (*) designates significant improvement (p < 0.05) in C-index relative to clinical
quantitative ER by dextran-charcoal coated ligand binding assay (DCC). Double asterisk (**)
designates significant improvement (p < 0.05) in C-index relative to visual quantitative Ki67
index.
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Comparison of prognostic classifiers in node negative subjects. The C-index is used to compare
accuracy of the prognostic classifiers (panel A and Supplemental Table S5). * designates
significant improvement (p < 0.05) in C-index relative to the clinical model (Adjuvant!) and
** to the IHC-T model. Taking the best-performing model, ROR-PT values are related to actual
10 year event probabilities using a Cox proportional hazard model (panel B, dotted lines are
95% CI). Kaplan-Meier survival analysis of the size and proliferation weighted Risk of Relapse
(ROR-PT) assignments are presented in panels C and D, and comparable information provided
by a model of IHC subtype and tumor size is shown in panels E and F. RFS = relapse-free
survival. DSS = breast cancer disease-specific survival (excludes two cases with unknown
cause of death)
Nielsen et al. Page 13














Comparison of prognostic classifiers in node positive subjects. A) C-index comparison of the
accuracy of prognostic classifiers as described in Figure 3. B) Cox proportional hazard model
relating the best performing model (ROR-T) to actual 10 year event probabilities. C) Kaplan-
Meier survival analysis of the size weighted Risk of Relapse (ROR-T) assignments for RFS
and (in panel D) DFS. E) and F) comparable information as provided by a model of IHC subtype
and tumor size.
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